ClinicalTrials.gg
Active, not recruitingNCT07705685Updated Jul 15, 2026

National Cohort Study on Infant Gut Microbiota and Nutrition

An observational study in Fecal Gut Microbiota, sponsored by DiproBio (Shanghai) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 0 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by DiproBio (Shanghai) Co., Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
106,667
Ages
0 Years to 6 Years
Sex
All
01

Study summary

This study plans to collect 106,667 fecal samples from Chinese infants and children under 6 years old, with multi-dimensional stratification based on geographic location, mode of delivery, antibiotic exposure, and developmental stage. Fecal gut microbiota will be profiled to construct a gut microbiome atlas, establish quantitative analytical models linking geographic regions, physiological phenotypes and microbial signatures, and identify key microbial biomarkers associated with core healthy phenotypes.

Read the detailed description

The human gastrointestinal tract harbors vast and diverse microbial communities collectively termed the "gut microbiota", widely known as the human body's "second genome". Research has demonstrated that during the colonization and maturation of gut microbiota in early infancy, these microbes participate in multiple core physiological processes including immune system maturation, nutrient absorption and metabolism, and nervous system development. Infancy represents a critical window for the establishment of intestinal microecology. Disturbances from adverse environmental factors such as antibiotic administration, inappropriate dietary patterns, and environmental pollution may trigger dysbiosis of microbial composition, which in turn elevates the long-term risk of developing obesity, allergic disorders, asthma, autism spectrum disorders and other diseases.

The formation and dynamic shifts of childhood gut microbiota are shaped not only by early-life exposures including mode of delivery, breastfeeding status and antibiotic use, but also by subsequent dietary patterns, living environments and socioeconomic status. For instance, high-fat diets reduce the abundance of beneficial gut bacteria, whereas Mediterranean-style diets support intestinal health; antibiotic treatment markedly diminishes microbial diversity and impairs community stability; urban-rural disparities also drive profound differences in gut microbial composition.

To date, domestic research on gut microbiota among infants and children has largely consisted of regional, small-cohort studies, lacking large-scale baseline datasets covering diverse geographic regions, age brackets and health statuses across China. This gap partially hinders the accumulation of scientific evidence for pediatric intestinal health research and disease prevention and control, and restricts the formulation of localized nutritional intervention strategies.

Accordingly, this study aims to conduct a large-cohort investigation covering infants and children aged 0 to 6 years nationwide. Through metagenomic sequencing and microbial isolation and culture of fecal specimens, we will construct gut microbiota atlases stratified by age, geographic region and health profile. The research will focus on associations between representative core gut taxa (e.g., Bifidobacterium) and indicators including children's nutritional status, immune development, allergic manifestations, gastrointestinal function and physical growth. We will also characterize microbial succession patterns during critical developmental windows in early life. Multivariate modeling and machine learning algorithms will be applied to screen microbial biomarkers strongly correlated with specific health conditions, and further dissect their underlying biological mechanisms.

This project is led by a professional research team with extensive experience in intestinal microecology. The team has previously completed gut microbiota profiling and analysis for thousands of infant subjects, obtained ethical approval and secured third-party laboratory qualification, laying a solid research foundation. Findings from this study will provide data support for early identification and intervention of common childhood illnesses, and deliver vital scientific evidence for developing personalized nutritional and health management strategies tailored to gut microecological signatures in Chinese children.

02

Conditions studied

  • Fecal Gut Microbiota
03

In context

Lead sponsor

DiproBio (Shanghai) Co., Ltd. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 6 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

A total of 106,667 Chinese infants and children aged 0 to 6 years will be enrolled across all 34 provincial-level administrative regions of China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants and children aged 0-6 years, regardless of gender.
  2. Volunteers willing to participate in fecal sample collection and baseline health information gathering during the study period.
  3. Legal guardians must agree to participate in the study and provide a signed written .

Exclusion criteria

Exclusion Criteria:

  1. Presence of congenital developmental anomalies, including but not limited to congenital cardiovascular malformations and chromosomal aneuploidy.
  2. Immune system functional disorders, such as Severe Combined Immunodeficiency.
  3. Diagnosis of hereditary diseases, such as genetic disorders caused by chromosomal abnormalities.
  4. Any condition deemed unsuitable for participation by the investigator, including but not limited to failure to meet compliance assessment standards.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
106,667 participants (estimated)
Patient registry
No

Groups and cohorts

  • National cohort of Chinese children aged 0-6 years

    This single nationwide cohort enrolls a total of 106,667 Chinese infants and children under 6 years old. enrollment.

    Other: Fecal sample collection and gut microbiome profiling

Interventions

  • OtherFecal sample collection and gut microbiome profiling

    This study is purely observational with no therapeutic or invasive clinical interventions implemented. We only collect non-invasive fecal specimens from enrolled healthy infants and children aged 0-6 years across China, perform microbial genome sequencing and microbial isolation culture to analyze gut microbiota characteristics, and construct a national pediatric gut microbiome atlas. No drugs, medical devices or clinical treatment adjustments are given to participants throughout the research.

06

What researchers measure

Primary outcomes

  1. Establish a national gut microbiome atlas of infants and children aged 0-6 years covering all 34 provincial-level administrative regions in China, incorporating subjects across distinct age brackets and geographic backgrounds

    Time frame: Baseline (single time point at enrollment)

07

Study locations

1 site
  • DiPROBIO(Shanghai) Co., Ltd.
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Mar 2030, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Mar 1, 2030
CompletionEst.
Mar 1, 2031
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07705685
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Apr 30, 2026
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2031 (estimated)
Last update
Jul 15, 2026

Study contacts

Qinghua Yu
principal investigator · DiproBio (Shanghai) Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion